Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bruce R Schackman

Showing results (131-140 of 222) with videos related to

Pageof 23
Sort By:
Drug and Alcohol Dependence Reports|March 20, 2026
Higher drug overdose mortality among non-hispanic black adults aged 55 and older in the U.S.: Analysis of national death records from CDC's WONDER database (1999-2023)Zongbo Li, Yanwei Jin, M Kumi Smith, et al.
JAMA Network Open|October 16, 2024
Health and Economic Outcomes of Offering Buprenorphine in Homeless Shelters in MassachusettsAvik Chatterjee, Emily A Stewart, Sabrina A Assoumou, et al.
Annals of Internal Medicine|December 18, 2018
Cost-Effectiveness of Buprenorphine-Naloxone Versus Extended-Release Naltrexone to Prevent Opioid RelapseSean M Murphy, Kathryn E McCollister, Jared A Leff, et al.
Drug and Alcohol Dependence|February 26, 2018
Cost-effectiveness of hepatitis C screening and treatment linkage intervention in US methadone maintenance treatment programsBruce R Schackman, Sarah Gutkind, Jake R Morgan, et al.
Drug and Alcohol Dependence|July 19, 2025
A geospatial analysis of naloxone distribution patterns in the Massachusetts overdose education and naloxone distribution program (MA OEND)Timothy W Levengood, Leah C Shaw, Xiao Zang, et al.
AIDS (London, England)|October 20, 2011
Newer drugs and earlier treatment: impact on lifetime cost of care for HIV-infected adultsCaroline E Sloan, Karen Champenois, Philippe Choisy, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 19, 2013
Racial differences in response to antiretroviral therapy for HIV infection: an AIDS clinical trials group (ACTG) study analysisHeather J Ribaudo, Kimberly Y Smith, Gregory K Robbins, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|February 6, 2009
HIV preexposure prophylaxis in the United States: impact on lifetime infection risk, clinical outcomes, and cost-effectivenessA David Paltiel, Kenneth A Freedberg, Callie A Scott, et al.
Sexually Transmitted Diseases|August 15, 2014
The cost of implementing rapid HIV testing in sexually transmitted disease clinics in the United StatesAshley A Eggman, Daniel J Feaster, Jared A Leff, et al.
Journal of the International Association of Providers of AIDS Care|February 26, 2019
Why Maximizing Quality-Adjusted Life Years, rather than Reducing HIV Incidence, Must Remain Our Objective in Addressing the HIV/AIDS EpidemicBohdan Nosyk, Jeong Eun Min, Xiao Zang, et al.
Pageof 23

Showing results (131-140 of 222) with videos related to

Sort By:
Pageof 23
Drug and Alcohol Dependence Reports|March 20, 2026
Higher drug overdose mortality among non-hispanic black adults aged 55 and older in the U.S.: Analysis of national death records from CDC's WONDER database (1999-2023)Zongbo Li, Yanwei Jin, M Kumi Smith, et al.
JAMA Network Open|October 16, 2024
Health and Economic Outcomes of Offering Buprenorphine in Homeless Shelters in MassachusettsAvik Chatterjee, Emily A Stewart, Sabrina A Assoumou, et al.
Annals of Internal Medicine|December 18, 2018
Cost-Effectiveness of Buprenorphine-Naloxone Versus Extended-Release Naltrexone to Prevent Opioid RelapseSean M Murphy, Kathryn E McCollister, Jared A Leff, et al.
Drug and Alcohol Dependence|February 26, 2018
Cost-effectiveness of hepatitis C screening and treatment linkage intervention in US methadone maintenance treatment programsBruce R Schackman, Sarah Gutkind, Jake R Morgan, et al.
Drug and Alcohol Dependence|July 19, 2025
A geospatial analysis of naloxone distribution patterns in the Massachusetts overdose education and naloxone distribution program (MA OEND)Timothy W Levengood, Leah C Shaw, Xiao Zang, et al.
AIDS (London, England)|October 20, 2011
Newer drugs and earlier treatment: impact on lifetime cost of care for HIV-infected adultsCaroline E Sloan, Karen Champenois, Philippe Choisy, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 19, 2013
Racial differences in response to antiretroviral therapy for HIV infection: an AIDS clinical trials group (ACTG) study analysisHeather J Ribaudo, Kimberly Y Smith, Gregory K Robbins, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|February 6, 2009
HIV preexposure prophylaxis in the United States: impact on lifetime infection risk, clinical outcomes, and cost-effectivenessA David Paltiel, Kenneth A Freedberg, Callie A Scott, et al.
Sexually Transmitted Diseases|August 15, 2014
The cost of implementing rapid HIV testing in sexually transmitted disease clinics in the United StatesAshley A Eggman, Daniel J Feaster, Jared A Leff, et al.
Journal of the International Association of Providers of AIDS Care|February 26, 2019
Why Maximizing Quality-Adjusted Life Years, rather than Reducing HIV Incidence, Must Remain Our Objective in Addressing the HIV/AIDS EpidemicBohdan Nosyk, Jeong Eun Min, Xiao Zang, et al.
Pageof 23